Alzheimer's disease
A study of over 375,000 Finns has linked hospital treatment for severe infections like cystitis and pneumonia to a higher risk of developing dementia within five to six years. Researchers identified 29 conditions associated with at least a 20 percent increased risk, with infections playing a key role. The findings suggest that preventing such infections could help modify dementia risk.
Von KI berichtet
Chinese biotech firm SciNeuro Pharmaceuticals has partnered with Swiss pharmaceutical giant Novartis in a deal worth nearly $1.7 billion to develop treatments for Alzheimer's disease, which affects some 55 million people worldwide. The agreement grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro's antibody candidates for the progressive brain disease. SciNeuro's novel amyloid beta-targeted antibody programme leverages proprietary blood-brain barrier shuttle technology to help more of the drug cross into the brain where Alzheimer's damage occurs.